NCT03335670View on ClinicalTrials.gov

Gallium 68 Pentixafor in Patients With Neuroendocrine Tumors

EARLY_PHASE1Active, not recruitingINTERVENTIONAL
Enrollment

30

Participants

Timeline

Start Date

November 3, 2017

Primary Completion Date

December 31, 2029

Study Completion Date

June 30, 2030

Conditions
Neuroendocrine Tumors
Interventions
DRUG

[68Ga]Pentixafor

68Ga Pentixafor is a radiolabeled cyclic pentapeptide with high affinity for CXCR4 receptor

Trial Locations (1)

52242

Holden Comprehensive Cancer Center, Iowa City

All Listed Sponsors
collaborator

National Cancer Institute (NCI)

NIH

collaborator

National Institutes of Health (NIH)

NIH

collaborator

Holden Comprehensive Cancer Center

OTHER

lead

Yusuf Menda

OTHER